Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen.
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Researchers establish a Chinese-specific BRCA database to cover nearly all of the BRCA variation information currently known across this population.